Get the Stockscreener App
23.99
0.29%
0.07
After Hours:
23.55
-0.44
-1.83%
Mineralys Therapeutics Inc stock is traded at $23.99, with a volume of 1.43M.
It is up +0.29% in the last 24 hours and down -12.38% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$23.92
Open:
$23.98
24h Volume:
1.43M
Relative Volume:
0.99
Market Cap:
$2.11B
Revenue:
-
Net Income/Loss:
$-151.78M
P/E Ratio:
-11.65
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
-0.79%
1M Performance:
-12.38%
6M Performance:
-33.44%
1Y Performance:
+78.36%
1-Day Range:
$23.29
$24.25
1-Week Range:
$23.26
$25.02
52-Week Range:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
23.99 | 2.11B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Blood protein shifts hint at heart failure pathways for lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise - Stock Titan
Akin, an Elite Global Law Firm - Akin
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Insider Monkey
Transcript : Mineralys Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering - Global Legal Chronicle
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
MLYS: Lorundrostat advances toward launch with strong clinical data, strategic deals, and broad payer support - TradingView
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - The Manila Times
Mineralys Therapeutics to Present Late-Breaking Data on - GlobeNewswire
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million - Legal Desire Media and Insights
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Yahoo Finance
Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Insider Monkey
Mineralys Therapeutics prices $150M stock offering - MSN
Latham Advises Mineralys Therapeutics in Unique Three-Pronged - Latham & Watkins LLP
Mineralys pays up to $300 million to clear lorundrostat royalties - The Pharma Letter
MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus
Mineralys announces $150 million equity offering and financing - TipRanks
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Moomoo
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet - Bez Kabli
Mineralys raises $750M through debt, equity and royalty deal By Investing.com - Investing.com India
Why Mineralys Therapeutics Stock Is Sliding Today - TipRanks
Mineralys prices $150 million stock offering at $26.50 per share By Investing.com - Investing.com South Africa
BioPharma Credit provides up to $150m loan to Mineralys By Investing.com - Investing.com Australia
BioPharma Credit provides up to $150m loan to Mineralys - Investing.com
Mineralys Secures Lorundrostat Rights and Major Financing Facility - TipRanks
Mineralys Therapeutics Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock - TradingView
Mineralys Therapeutics Announces Repurchase Of Royalty Obligations In Tanabe License Agreement And Concurrent Financing - TradingView
Mineralys prices $150 million stock offering at $26.50 per share - Investing.com UK
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Mineralys raises $750M through debt, equity and royalty deal - Investing.com
Mineralys Locks In Royalty-Free Lorundrostat Rights With $200M Payment, Secures $500M Term Loan - TradingView
Mineralys Therapeutics Prices Underwritten Offering of 5.6 Million Shares at $26.50 Per Share, Expected to Raise $150 Million - Quiver Quantitative
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing - The Manila Times
Mineralys (NASDAQ: MLYS) gets $500M loan, ends lorundrostat royalty payments - Stock Titan
Mineralys Therapeutics, Inc. Enters into Senior Secured Term Loan Agreement for Up to $500 Million - marketscreener.com
Jefferies reiterates Hold on Mineralys stock amid M&A speculation By Investing.com - Investing.com Australia
Velan Capital Cuts Mineralys Therapeutics Stake by 140000 Shares - asatunews.co.id
Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular ProtectionSlideshow (NASDAQ:MLYS) 2026-06-01 - Seeking Alpha
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Jun 10 '26 |
Option Exercise |
16.00 |
2,170 |
34,720 |
65,613 |
| Rodman David Malcom | Chief Medical Officer |
Jun 12 '26 |
Option Exercise |
1.08 |
6,349 |
6,857 |
69,792 |
| Rodman David Malcom | Chief Medical Officer |
Jun 12 '26 |
Sale |
23.93 |
6,349 |
151,901 |
63,443 |
| Rodman David Malcom | Chief Medical Officer |
Jun 10 '26 |
Sale |
25.00 |
2,170 |
54,250 |
63,443 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):